33.40
-0.35 (-1.04%)
| Previous Close | 33.75 |
| Open | 33.53 |
| Volume | 426,193 |
| Avg. Volume (3M) | 563,482 |
| Market Cap | 1,670,420,864 |
| Price / Sales | 3.37 |
| Price / Book | 3.59 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 |
| Profit Margin | -9.61% |
| Operating Margin (TTM) | -11.69% |
| Diluted EPS (TTM) | -0.950 |
| Quarterly Revenue Growth (YOY) | 16.60% |
| Total Debt/Equity (MRQ) | 16.60% |
| Current Ratio (MRQ) | 3.65 |
| Operating Cash Flow (TTM) | 12.20 M |
| Levered Free Cash Flow (TTM) | -10.42 M |
| Return on Assets (TTM) | -4.09% |
| Return on Equity (TTM) | -9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | AtriCure, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 1.5 |
| Average | 1.25 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 97.36% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Citizens Capital Markets, 79.64%) | Buy |
| 60.00 (JMP Securities, 79.64%) | Buy | |
| Median | 50.00 (49.70%) | |
| Low | 44.00 (Needham, 31.74%) | Buy |
| Average | 51.44 (54.01%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 35.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 30 Apr 2025 | 60.00 (79.64%) | Buy | 33.40 |
| 13 Feb 2025 | 60.00 (79.64%) | Buy | 39.59 | |
| Needham | 30 Apr 2025 | 44.00 (31.74%) | Buy | 33.40 |
| 27 Mar 2025 | 51.00 (52.69%) | Buy | 34.37 | |
| UBS | 30 Apr 2025 | 58.00 (73.65%) | Buy | 33.40 |
| Citizens Capital Markets | 02 Apr 2025 | 60.00 (79.64%) | Buy | 34.13 |
| Canaccord Genuity | 28 Mar 2025 | 52.00 (55.69%) | Buy | 31.83 |
| 13 Feb 2025 | 66.00 (97.60%) | Buy | 39.59 | |
| JP Morgan | 27 Mar 2025 | 46.00 (37.72%) | Buy | 34.37 |
| 11 Feb 2025 | 51.00 (52.69%) | Buy | 41.51 | |
| Oppenheimer | 13 Feb 2025 | 45.00 (34.73%) | Buy | 39.59 |
| Piper Sandler | 13 Feb 2025 | 50.00 (49.70%) | Buy | 39.59 |
| Stifel | 13 Feb 2025 | 48.00 (43.71%) | Buy | 39.59 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Apr 2025 | Announcement | AtriCure Reports First Quarter 2025 Financial Results |
| 10 Apr 2025 | Announcement | AtriCure Announces First Use of the AtriClip PRO-Mini® Device |
| 08 Apr 2025 | Announcement | AtriCure to Announce First Quarter 2025 Financial Results |
| 12 Mar 2025 | Announcement | AtriCure to Host Analyst & Investor Day on March 26, 2025 |
| 12 Feb 2025 | Announcement | AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |